Paying users zone. Data is covered by 
.
Get 1 month access to Bristol-Myers Squibb Co. for $17.99, or
get full access to entire website for at least 3 months from $49.99.
We accept:
Bristol-Myers Squibb Co. (BMY)
Statement of Cash Flows
Quarterly Data
Difficulty: Beginner
The cash flow statement provides information about a company’s cash receipts and cash payments during an accounting period, showing how these cash flaws link the ending cash balance to the beginning balance shown on the company’s statement of financial position.
The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.
Bristol-Myers Squibb Co., Consolidated Statement of Cash Flows (quarterly data)
USD $ in millions
Based on: 10-Q (filing date: 2019-04-25), 10-K (filing date: 2019-02-25), 10-Q (filing date: 2018-10-25), 10-Q (filing date: 2018-07-26), 10-Q (filing date: 2018-04-26), 10-K (filing date: 2018-02-13), 10-Q (filing date: 2017-10-26), 10-Q (filing date: 2017-07-27), 10-Q (filing date: 2017-04-27), 10-K (filing date: 2017-02-21), 10-Q (filing date: 2016-10-27), 10-Q (filing date: 2016-07-28), 10-Q (filing date: 2016-04-28), 10-K (filing date: 2016-02-12), 10-Q (filing date: 2015-10-27), 10-Q (filing date: 2015-07-23), 10-Q (filing date: 2015-04-28), 10-K (filing date: 2015-02-13), 10-Q (filing date: 2014-10-24), 10-Q (filing date: 2014-07-24), 10-Q (filing date: 2014-04-29).
| Item | Description | The company |
|---|---|---|
| Net cash provided by (used in) operating activities | Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. | Bristol-Myers Squibb Co.’s net cash provided by (used in) operating activities increased from Q3 2018 to Q4 2018 but then slightly declined from Q4 2018 to Q1 2019 not reaching Q3 2018 level. |
| Net cash (used in) provided by investing activities | Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. | Bristol-Myers Squibb Co.’s net cash (used in) provided by investing activities declined from Q3 2018 to Q4 2018 but then increased from Q4 2018 to Q1 2019 exceeding Q3 2018 level. |
| Net cash used in financing activities | Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. | Bristol-Myers Squibb Co.’s net cash used in financing activities increased from Q3 2018 to Q4 2018 but then declined significantly from Q4 2018 to Q1 2019. |